Evidence map›Paper›PMID 41897327›Full record

ArticleBiomolecules2026

Selective Silencing of TDP-43 P. G376D Mutation Reverses Key Amyotrophic Lateral Sclerosis-Related Cellular Deficits.

Roberta Romano, Giorgia Ruotolo, Francesco Perrone, Silvia Tomaselli, Martina Mazzoni, Rossella Spataro, Francesca Luisa Conforti, Jessica Rosati, Cecilia Bucci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Roberta RomanoDepartment of Experimental Medicine, University of Salento, 73100 Lecce, Italy.ORCID 0000-0002-4987-3561
Giorgia RuotoloCell Reprogramming Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.ORCID 0000-0002-6366-6868
Francesco PerroneDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
Silvia TomaselliCell Reprogramming Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.
Martina MazzoniCell Reprogramming Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.
Rossella SpataroIntensive Neurorehabilitation Unit, Villa delle Ginestre Hospital, 90135 Palermo, Italy.
Francesca Luisa ConfortiDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.ORCID 0000-0001-8364-1783
Jessica RosatiCell Reprogramming Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.
Cecilia BucciDepartment of Experimental Medicine, University of Salento, 73100 Lecce, Italy.ORCID 0000-0002-6232-6183

Funding

Ministero dell'università e della ricerca PRIN2022 N. 2022XTM2S3
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease for which there is currently no cure. Dominant mutations in the

Indexed as

Amyotrophic Lateral SclerosisDNA-Binding ProteinsGene SilencingMutationCell SurvivalHumansInduced Pluripotent Stem CellsMotor NeuronsOxidative StressRNA, Small InterferingDNA-Binding ProteinsRNA, Small InterferingTARDBP protein, humanALSmotor neuronRNA interferenceTARDBP

Identifiers

PMID41897327
PMCPMC13024069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.